莫昔普利盐酸盐 T6595

Product Introduction
Bioactivity


英文名: Moexipril hydrochloride

描述: Moexipril hydrochloride (Moexipril HCl) 是一种有口服活性的，不含巯基的血管紧张素转化酶抑制剂，可治疗高血压和充血性心力衰竭。

体外活性: Moexipril dose-dependently reduces the percentage of damaged neurons, as well as mitochondrial reactive oxygen species generation induced by glutamate, staurosporine or Fe2+/3+. Moexipril and enalapril attenuates staurosporine-induced neuronal apoptosis as determined by nuclear staining with Hoechst 33258. [1]

体内活性: Moexipril (0.3 mg/kg) significantly reduces brain damage after focal ischemia as compared to control mice. Moexipril (0.01 mg/kg) is able to reduce the infarct volume in the rat model after focal cerebral ischemia. [1] Moexipril reduces blood pressure after the first week of treatment but it has no apparent effect on either the proximal tibial metaphysis or the tibial shaft in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Moexipril combined with hydrochlorothiazide (HCTZ) exhibits a much more potent hypotensive effect and has the same effect on bone mass and dynamic end-points as HCTZ alone. [2] Moexiprilat exhibits a higher inhibitory potency than enalaprilat against both plasma ACE and purified ACE from rabbit lung. Moexipril (0.1-30 mg/kg/day) lowers blood pressure and differentially inhibits ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion. Moexipril (10 mg/kg/day) leads to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin. [3]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 53.5 mg/mL (100 mM)


关键字: orally active | Apoptosis | Ischemic brain injury | inhibit | hepatic disease | Angiotensin-converting Enzyme (ACE) | hydrochlorothiazide | essential hypertension | Moexipril hydrochloride | antihypertensive | moexiprilat | angiotensin II | Moexipril Hydrochloride | SPM925 | cardiovascular disease | Inhibitor | RS 10085 | CI 925 | CI925 | SPM-925 | hypertension | RS10085 | Moexipril

相关产品: Nebivolol hydrochloride | Vistusertib | AMAROGENTIN | Pseudolaric Acid B | Hydroxy-PP-Me | SKI-178 | Indirubin | Ruxolitinib | Alofanib | Sacubitril/Valsartan

相关库: Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Clinical Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compound Library

莫昔普利盐酸盐 T6595信息由TargetMol中国为您提供，如您想了解更多关于莫昔普利盐酸盐 T6595报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途